Company / R&D Expense
SANGAMO THERAPEUTICS, INC R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$112.7M
FY2025
5-year range
$111.5M / $249.9M
FY2021-FY2025
Trend
+1.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $113M.
Based on SEC 10-K filings.
$113M in FY2025 with a 5-year CAGR of -9.0%.
Declined from $234M to $113M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -23.3%
- 5-Year CAGR
- -9.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -9.0%, indicating a declining trend.
- In FY2025, r&d expense increased 1.0% year-over-year.
- Peak r&d expense was recorded in FY2022.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -28.87 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $112.7M | +1.0% |
| FY2024 | $111.5M | -52.4% |
| FY2023 | $234.1M | -6.3% |
| FY2022 | $249.9M | +8.3% |
| FY2021 | $230.8M | +27.8% |
| FY2020 | $180.6M | +23.8% |
| FY2019 | $145.9M | +27.0% |
| FY2018 | $114.9M | +74.8% |
| FY2017 | $65.7M | +0.2% |
| FY2016 | $65.6M | -2.4% |